Dietrich Matern, M.D., Ph.D., discusses the importance of newborn screening, the conditions included within the Recommended Universal Screening Panel, and the new newborn screening panels available through Mayo Medical Laboratories.
The recommendations surrounding newborn screening are constantly in flux. Newly discovered treatments or emerging laboratory technologies are enabling additional recommendations for newborn screening.
In cases of sudden or unexpected death, autopsy evaluation can include a biochemical analysis to identify deaths caused by fatty acid oxidation disorders.
Silvia Tortorelli, M.D., Ph.D., Consultant in Laboratory Genetics at Mayo Clinic, recently published an article on Mayo’s efficient and cost-effective multiplex assay.
Registration is now open for Mayo Medical Laboratories’ Genetic Testing Forum, Advanced in Newborn Screening. The forum will be held September 8 from 12—1 p.m. Central Time.
Newborn screening (NBS) has developed throughout the years into a public health prevention program aimed at identifying an increasing number of conditions for which early intervention can prevent premature mortality, morbidity, and disabilities. In a recent article published in the journal Seminars in Perinatology, Mayo Clinic researchers reviewed the current state of NBS for lysosomal storage disorders and discussed their importance in NBS programs.